Hydroxychloroquine

Generic Name: Hydroxychloroquine

Brand Names: Plaquenil, Sovuna

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₆ClN_₃O

CAS Number: 118-42-3

Unique Ingredient Identifier: 4QWG6N8QKH

Background: Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.

The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.

Hydroxychloroquine was granted FDA approval on 18 April 1955.

A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.

Indication: Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.

Associated Conditions: Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum

Clinical Trials

Public Health Emergency: SOLIDARITY TRIAL Philippines

Not Applicable

Completed

Conditions: Covid19

Interventions: Drug: Remdesivir
Drug: Lopinavir / Ritonavir
Drug: Hydroxychloroquine
Drug: Acalabrutinib
Drug: Interferon beta-1a

First Posted Date: 2021-08-27

Last Posted Date: 2022-03-02

Lead Sponsor: University of the Philippines

Target Recruit Count: 1314

Registration Number: NCT05024006

Locations: 🇵🇭
Chinese General Hospital, Manila, Metro Manila, Philippines
🇵🇭
UP - Philippine General Hospital, Manila, Metro Manila, Philippines
🇵🇭
San Juan de Dios Educational Foundation Inc - Hospital, Pasay, Metro Manila, Philippines

and more 22 locations

Efficacy and Safety of Baricitinib in Sjogren's Syndrome

Phase 2

Completed

Conditions: Sjogren's Syndrome

Interventions: Drug: Baricitinib
Drug: Hydroxychloroquine

First Posted Date: 2021-08-23

Last Posted Date: 2024-12-11

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 90

Registration Number: NCT05016297

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Hydroxychloroquine and Indapamide in SPMS

Phase 2

Recruiting

Conditions: Multiple Sclerosis, Secondary Progressive

Interventions: Drug: Hydroxychloroquine Pill
Drug: Indapamide Pill

First Posted Date: 2021-08-19

Last Posted Date: 2022-05-18

Lead Sponsor: University of Calgary

Target Recruit Count: 35

Registration Number: NCT05013463

Locations: 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada

Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment

Phase 3

Completed

Conditions: Covid19

Interventions: Drug: Favipiravir + Hydroxychloroquine
Drug: Hydroxychloroquine
Drug: Placebo
Drug: Favipiravir

First Posted Date: 2021-07-29

Last Posted Date: 2021-07-29

Lead Sponsor: Health Institutes of Turkey

Target Recruit Count: 1120

Registration Number: NCT04981379

Locations: 🇹🇷
Ankara City Hospital, Ankara, Turkey
🇹🇷
Istanbul University Istanbul Medicine Faculty, Istanbul, Turkey
🇹🇷
Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Istanbul, Turkey

and more 3 locations

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Phase 4

Recruiting

Conditions: Primary Sjögren's Syndrome

Interventions: Drug: Iguratimod Tablets
Drug: Hydroxychloroquine Sulfate Tablets

First Posted Date: 2021-07-28

Last Posted Date: 2024-10-16

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 78

Registration Number: NCT04981145

Locations: 🇨🇳
Second affiliated hospital of zhejiang university，school of medical, Hangzhou, Zhejiang, China

A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nipocalimab
Drug: Hydroxychloroquine
Drug: Etanercept

First Posted Date: 2021-07-22

Last Posted Date: 2025-03-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 48

Registration Number: NCT04973566

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19

Phase 2

Conditions: Covid19

Interventions: Drug: Hydroxychloroquine with Azithromycin

First Posted Date: 2021-07-16

Last Posted Date: 2021-08-04

Lead Sponsor: Coordinación de Investigación en Salud, Mexico

Target Recruit Count: 105

Registration Number: NCT04964583

Locations: 🇲🇽
UMF 28, Benito Juárez, Mexico City, Mexico
🇲🇽
Fundación IMSS, Cuauhtémoc, Mexico City, Mexico
🇲🇽
UMF 52, Cuautitlán Izcalli, State Of Mexico, Mexico